Drug Information

Drug (ID: DG01796) and It's Reported Resistant Information

• Name: Streptozocin
• Synonyms: Streptozocin; STREPTOZOTOCIN; streptozosin; 18883-66-4; Zanosar; Estreptozocina; Streptozocine; Streptozocinium; Streptozocinum; 2-Desoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 66395-18-4; N-D-Glucosyl-(2)-N'-nitrosomethylurea; C8H15N3O7; alpha-Streptozocin; streptozotocin (stz); CHEBI:9288; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; UNII-8H27GUR065; 8H27GUR065; MFCD00006607; STZ; alkylating agent; NSC-85998; DSSTox_CID_1282; DSSTox_RID_76055; DSSTox_GSID_21282; binds to DNA; Zanosar (TN); SR-05000001720; 2-deoxy-2-[[(methylnitrosoamino)carbonyl]amino]-D-glucose; 2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-alpha-D-glucopyranose; NCGC00016738-01; CAS-18883-66-4; Spectrum_000960; Streptozotocin - Zanosar; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose; Prestwick3_000732; Spectrum2_000062; Spectrum3_001087; Spectrum4_001244; Spectrum5_001047; Epitope ID:134282; N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; SCHEMBL4748; Streptozocin; Streptozotocin; CHEMBL1603; BSPBio_000684; BSPBio_002734; KBioGR_001768; KBioSS_001440; MLS004774123; DivK1c_000531; SPECTRUM1500543; SPBio_000243; BPBio1_000754; Streptozocin (JAN/USAN/INN); DTXSID2021282; BCBcMAP01_000142; HMS501K13; KBio1_000531; KBio2_001440; KBio2_004008; KBio2_006576; KBio3_001954; NINDS_000531; HMS1921A07; HMS2092I09; HMS2097C06; HMS3714C06; Pharmakon1600-01500543; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; ACT03364; ZINC3977737; Streptozocin, >=98.0% (HPLC); Tox21_110585; Tox21_201859; Tox21_302974; CCG-39870; NSC757321; s1312; AKOS025310730; Tox21_110585_1; DB00428; NSC-757321; IDI1_000531; SMP1_000282; NCGC00178500-01; NCGC00178500-02; NCGC00178500-03; NCGC00178500-04; NCGC00178500-07; NCGC00256594-01; NCGC00259408-01; 1-methyl-1-nitroso-3-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)urea; SMR001233317; SBI-0051517.P003; AB00513906; SW199198-2; C07313; D05932; AB00052092-03; AB00052092_04; AB00052092_05; 883S664; A937380; N-(METHYLNITROSOCARBAMOYL)-A-D-GLUCOSAMINE; Q257331; SR-01000939745; SR-01000939745-3; SR-05000001720-1; SR-05000001720-2; W-201687; Streptozocin, Vetec(TM) reagent grade, 98%, powder; Streptozocin, >=75% alpha-anomer basis, >=98% (HPLC), powder; alpha-D-Glucopyranose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-; WURCS=2.0/1,1,0/[a2122h-1a_1-5_2*NCNN=O/4C/3=O]/1/; 3-methyl-3-nitroso-1-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 1-Methyl-1-nitroso-3-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-3-yl)urea; 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl]urea
• Indication:
  In total 1 Indication(s)
  Pancreatic cancer [ICD-11: 2C10]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Chronic kidney disease [ICD-11: GB61]; [1]
• Target: Human Deoxyribonucleic acid (hDNA); NOUNIPROTAC; [1]
• Formula: 2
• IsoSMILES: CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O
• InChI: InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1
• InChIKey: ZSJLQEPLLKMAKR-GKHCUFPYSA-N
• PubChem CID: 29327
• ChEBI ID: CHEBI:9288
• TTD Drug ID: D0I8RR
• DrugBank ID: DB00428

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-16: Genitourinary system diseases

Chronic kidney disease [ICD-11: GB61]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Growth arrest specific 5 (GAS5) [1]

• Molecule Alteration: Down-regulation; Interaction
• Resistant Disease: Chronic kidney disease [ICD-11: GB61.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Renal tubular epithelial cells; N.A.; .; N.A.
• Experiment for Molecule Alteration: qRT-PCR; Western bloting analysis; Overexpression assay; RIP experiments assay; RNA pull down assay; ChIP assay
• Mechanism Description: Long noncoding RNA growth arrest-specific transcript 5 alleviates renal fibrosis in diabetic nephropathy by downregulating matrix metalloproteinase 9 through recruitment of enhancer of zeste homolog 2.

References

• Ref 1: Long noncoding RNA growth arrest-specific transcript 5 alleviates renal fibrosis in diabetic nephropathy by downregulating matrix metalloproteinase 9 through recruitment of enhancer of zeste homolog 2FASEB J. 2020 Feb;34(2):2703-2714. doi: 10.1096/fj.201901380RR. Epub 2020 Jan 9.